What is palbociclib?

Palbociclib (Chinese name: 帕博西布) is a CDK4/6 inhibitor developed by Pfizer for the treatment of HR+/HER2- advanced breast cancer. Its trade name is Ibrance , which can delay the growth of cancer cells and significantly improve the efficacy when used in combination with endocrine therapy.

Palbociclib market status and price in China

Palbociclib was approved for marketing by the China National Medical Products Administration in 2020. It has been included in the medical insurance catalogue of some cities. The price is about RMB 25,000 per box (125 mg x 21 tablets) without reimbursement . The price will be reduced after medical insurance reimbursement, but its use is limited by indications and medical history conditions.

Palbociclib in Hong Kong: Obvious price advantage

In Hong Kong , Palbociclib (Ibrance) is officially supplied by Pfizer and sold freely in pharmacies at a price of about HK$13,000 to HK$17,000 per box. No medical insurance review is required, and the acquisition is more flexible, which has attracted a large number of patients from mainland China to purchase or obtain through cross-border intermediaries.

Comparison of Pfizer's marketing strategies in China and Hong Kong

• Mainland China : Drugs are included in medical insurance, but reimbursement conditions are relatively strict; out-of-pocket prices are still relatively high.
• Hong Kong : Market-based pricing, unlimited use, and relatively favorable prices.

Palbociclib Acquisition Advice and Risk Warning

Palbociclib is not suitable for all breast cancer patients and is recommended to be used under the guidance of a doctor. Common side effects include decreased white blood cells, anemia, increased risk of infection, etc. Regular monitoring of blood routine is necessary.

• Palbociclib price in China
• Palbociclib Hong Kong purchase medicine
• Pfizer Ibrance
• Where can I buy Ibrance in Hong Kong
• Palbociclib original drug price comparison